Dergiler / Eurasian Journal of Medical Investigation / 2021 / Cilt: 5 - Sayı: 2

Desmoid Tumours: A single-centre Experience

Sayfa
180–183
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Large-scale studiesare needed to determine the biological characteristics of this extremely rare disease, the optimization of treatment op tions, and the determination of prognostic factors.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: To reveal the main patient and disease characteristics, treatment management and clinical course of des moid tumours.
📊
Temel Bulgular & Veri:Results: Of the 11 patients with a median age of 33.0 (12.1-63.1), 7 (63.6%) were female, and 4 (36.4%) were male.
💡
Sonuç & Katkı:Large-scale studiesare needed to determine the biological characteristics of this extremely rare disease, the optimization of treatment op tions, and the determination of prognostic factors.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: To reveal the main patient and disease characteristics, treatment management and clinical course of des moid tumours. Methods: Patients with a diagnosis of desmoid tumour were evaluated retrospectively. Results: Of the 11 patients with a median age of 33.0 (12.1-63.1), 7 (63.6%) were female, and 4 (36.4%) were male. Loca tions were intraabdominal region, abdominal wall, thoracic wall and lower extremity in 5 (45.5%), 4 (36.4%), 1 (9.1%)and 1 (9.1%) patients, respectively. Two patients (18.2%) had a diagnosis of Familial Adenomatous Polyposis (FAP).Pregnancy and cesarean section in 1 (9.1%) and surgical trauma in 2 (18.2%) patients were the etiological factors. Theprimary treatment of 10 (90.9%) patients was surgery, and 1 (9.1%) patient was radiotherapy (RT). A second surgicalintervention was performed in four patients (36.4%) due to recurrence or progression. Three (27.3%) and 5 (45.5%) pa tients had received RT and systemic treatments, respectively. Mean overall survival was 130.2 ± 25.0 (95% CI, 81.1-179.2)months, and 3 (27.3%) patients died in follow-up. Conclusion: Desmoid tumours can present with very different clinical behaviours among patients. Large-scale studiesare needed to determine the biological characteristics of this extremely rare disease, the optimization of treatment op tions, and the determination of prognostic factors.

🔖

Bu Makaleye Atıf Yap

ERASLAN, E., YİLDİZ, F., ILHAN, A., DOGAN, M. (2022). Desmoid Tumours: A single-centre Experience. Eurasian Journal of Medical Investigation, Cilt: 5 - Sayı: 2, 180–183. https://ajindex.com/articles/508581

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Kasper B, Ströbel P, Hohenberger P. Desmoid tumors: clinical features and treatment options for advanced disease. Oncologist 2011;16:682–93
  2. Mitchell G, Thomas JM, Harmer CL. Aggressive fibromatosis: evidence for a stable phase. Sarcoma 1998;2:149–54. 3. de Camargo VP, Keohan ML, D'Adamo DR, Antonescu CR, Brennan MF, Singer S, et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer 2010;116:2258–65
  3. Lev D, Kotilingam D, Wei C, Ballo MT, Zagars GK, Pisters PW, et al. Optimizing treatment of desmoid tumors. J Clin Oncol 2007;25:1785–91
  4. Klemmer S, Pascoe L, DeCosse J. Occurrence of desmoids in patients with familial adenomatous polyposis of the colon. Am J Med Genet 1987;28:385–92
  5. Fiore M, MacNeill A, Gronchi A, Colombo C. Desmoid-type fibromatosis: evolving treatment standards. Surg Oncol Clin N Am 2016;25:803–26
  6. Mankin HJ, Hornicek FJ, Springfield DS. Extra-abdominal desmoid tumors: a report of 234 cases. J Surg Oncol 2010;102:380–4
  7. Nieuwenhuis MH, Lefevre JH, Bülow S, Järvinen H, Bertario L, Kernéis S, et al. Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. Dis Colon Rectum 2011;54:1229–34
  8. Koskenvuo L, Peltomäki P, Renkonen-Sinisalo L, Gylling A, Nieminen TT, Ristimäki A, et al. Desmoid tumor patients carry an elevated risk of familial adenomatous polyposis. J Surg Oncol 2016;113:209–12
  9. Papagelopoulos PJ, Mavrogenis AF, Mitsiokapa EA, Papaparaskeva KT, Galanis EC, Soucacos PN. Current trends in the management of extra-abdominal desmoid tumours. World J Surg Oncol 2006;4:21
  10. Salas S, Dufresne A, Bui B, Blay JY, Terrier P, Ranchere-Vince D, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a waitand-see policy according to tumor presentation. J Clin Oncol 2011;29:3553–8
  11. Bonvalot S, Eldweny H, Haddad V, Rimareix F, Missenard G, Oberlin O, et al. Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 2008;34:462–8
  12. Gentile M, Jacobson A, Wang H, Goldberg S, Choy E, Mullen J, et al. Outcomes in patients with recurrent desmoid tumor managed with surgery alone, combined surgery and radiation therapy, or radiation therapy alone. IJROBP 2016;96:E704–E5
  13. NCCN guidelines soft tissue sarcoma version 1.2021; 2021. Available at: https://www.nccn